Abstract
Background The role of blood uric acid and more recently bilirubin as biomarkers in symptomatic motor PD has been increasingly established in the literature.
Objective Our present study assessed the role of serum uric acid and total bilirubin as putative biomarkers in a prodromal PD cohort followed longitudinally.
Methods Longitudinal 5-year serum uric acid and total bilirubin measurement data of 65 Prodromal PD patients (including REM Sleep Behavior disorder (RBD), N=39 and Hyposmia, N=26) with an abnormal DATSCAN imaging were downloaded from the Parkinson’s Progression Markers Initiative (PPMI) database. This cohort was compared with 423 de novo sporadic PD patients and 196 healthy controls enrolled in the same study.
Results After adjusting for age, sex and Body Mass Index (BMI), baseline and 5-year longitudinal serum uric acid levels were higher in the Prodromal cohort and RBD subgroup as compared to the motor PD cohort. This was also true for longitudinal measurements in the Hyposmic subgroup. In contrast, baseline and longitudinal serum total bilirubin did not differ between each prodromal group and the PD cohort.
Conclusions Our results are indicative of a role of serum uric acid (but probably not of total bilirubin) as a marker of neuroprotection, in a certain subgroup of premotor patients exhibiting exclusively non motor features (hyposmia or RBD). It is possible that an inherent antioxidant resistance of a subset of RBD or hyposmia patients with high serum uric acid level delayed or precluded the emergence of a motor PD phenotype as opposed to the PD cohort.
Competing Interest Statement
Christos Koros received funding from the Michael J Fox Foundation for his participation in PPMI. Athina-Maria Simitsi received funding from the Michael J Fox Foundation for her participation in PPMI. Anastasia Bougea has no disclosures. Nikolaos Papagiannakis has no disclosures. Andreas Prentakis has no disclosures. Dimitra Papadimitriou has no disclosures. Ioanna Pachi has no disclosures. Efthalia Angelopoulou has no disclosures. Konstantinos Lourentzos has no disclosures. Ion Beratis received funding from the Micheal J Fox Foundation for his participation in PPMI. Maria Bozi has no disclosures. Sokratis G Papageorgiou has no disclosures. Xenia Geronikola Trapali has no disclosures. Anastasios Bonakis has no disclosures. Maria Stamelou, serves on the editorial boards of Movement Disorders Journal and Frontiers in Movement Disorders, received travel and speaker honoraria from Abbvie, UCB and Specifar Pharmaceuticals, and the International Parkinson's disease and Movement Disorders Society, receives research support from the Michael J Fox Foundation (PPMI), royalties from Oxford University Press, Cambridge University Press, and Elsevier. Leonidas Stefanis is employed by the National and Kapodistrian University of Athens, Medical School and the Biomedical Research Foundation of the Academy of Athens. He has received the following grants : MULTISYN European Program (EU, FP7-HEALTH.2013.1.2-1, number 602646), PPMI (supported by the Michael J. Fox Foundation), IMPRIND-IMI2 Number 116060 (EU, H2020), SANTE Research Grant in Biomedical Sciences, NO-MND (EU-FP7-PEOPLE-2013-IRSES), NPF 2015 Investigator Award (Collaborator), PBMC and urine collection in LRRK2 and idiopathic PD Grant by the Michael J. Fox Foundation (Collaborator).
Funding Statement
This work was supported by funding from the PPMI study, Parkinson's Progression Markers Initiative. PPMI - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeek, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Servier, Teva, UCB, and Golub Capital.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
